Conversion from failed antireflux surgery to RefluxStop: A multicenter feasibility, technical evaluation, safety, and effectiveness study with 30 consecutive cases - Report - MDSpire
Advertisement
Conversion from failed antireflux surgery to RefluxStop: A multicenter feasibility, technical evaluation, safety, and effectiveness study with 30 consecutive cases
Clinical Report: Transitioning from Ineffective Antireflux Surgery to RefluxStop
Overview
This study evaluates the feasibility and outcomes of converting to RefluxStop after failed antireflux surgery (ARS) in 30 consecutive cases. The findings suggest that RefluxStop may be a viable option for patients who have not achieved satisfactory results from previous ARS.
Background
Gastroesophageal reflux disease (GERD) often requires surgical intervention, with antireflux surgery (ARS) achieving satisfactory outcomes in 85-90% of cases. However, a significant portion of patients experience treatment failure, leading to complications and the need for reoperation, which is associated with increased morbidity. The introduction of RefluxStop offers a potential alternative for patients with complex cases where traditional ARS has failed.
Data Highlights
No numerical data was provided in the source material.
Key Findings
RefluxStop surgery was performed laparoscopically in patients with failed ARS.
The study included 30 consecutive cases, all of whom provided informed consent.
General contraindications for the procedure included pregnancy, silicone allergy, and history of malignancy.
RefluxStop has shown promising outcomes in previous studies, with significant improvements in GERD-related quality of life.
Conversion to RefluxStop may mitigate the challenges associated with reoperation after traditional ARS.
Clinical Implications
The findings indicate that RefluxStop may be a suitable option for patients who have not responded to previous ARS. Clinicians should consider this approach in cases of treatment failure, especially in patients with complex GERD presentations.
Conclusion
RefluxStop presents a feasible alternative for patients with failed ARS, potentially improving outcomes in this challenging population.